Search company, investor...

Adams Respiratory Therapeutics

Founded Year



Acq - P2P | Acquired

Total Raised






About Adams Respiratory Therapeutics

Adams is a specialty pharmaceutical company focused on late stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. Adams was acquired by Reckitt Benckiser in January 2008.

Headquarters Location

4 Mill Ridge Lane Mill Ridge Farm

Chester, New Jersey, 07930,

United States


Missing: Adams Respiratory Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Adams Respiratory Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Adams Respiratory Therapeutics News

Perrigo Cleared For Generic Mucinex

Jan 16, 2012

Perrigo Company (NASDAQ:PRGO) recently announced that it has won a summary judgment in the patent case involving the generic version of Adams Respiratory Therapeutics’ drug Mucinex.  Adams Respiratory Therapeutics is a subsidiary of Reckitt Benckiser Group. Perrigo had received approval for its generic version of Mucinex in December 2011. It plans to launch the drug within the next 90 days. Mucinex indicated to relieve chest congestion has been identified as one of the important product … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards

Adams Respiratory Therapeutics Frequently Asked Questions (FAQ)

  • When was Adams Respiratory Therapeutics founded?

    Adams Respiratory Therapeutics was founded in 1997.

  • Where is Adams Respiratory Therapeutics's headquarters?

    Adams Respiratory Therapeutics's headquarters is located at 4 Mill Ridge Lane, Chester.

  • What is Adams Respiratory Therapeutics's latest funding round?

    Adams Respiratory Therapeutics's latest funding round is Acq - P2P.

  • How much did Adams Respiratory Therapeutics raise?

    Adams Respiratory Therapeutics raised a total of $31.41M.

  • Who are the investors of Adams Respiratory Therapeutics?

    Investors of Adams Respiratory Therapeutics include Reckitt Benckiser, Merrill, Equity Group Investments, Marquette Venture Partners, Talon Asset Management and 5 more.

  • Who are Adams Respiratory Therapeutics's competitors?

    Competitors of Adams Respiratory Therapeutics include Neurelis, Ology Bioservices, Acura Pharmaceuticals, Charleston Laboratories, Aerogen, Collegium Pharmaceutical, Meritage Pharma, Auxilium Pharmaceuticals, Questcor Pharmaceuticals, Acton Pharmaceuticals and 20 more.

Compare Adams Respiratory Therapeutics to Competitors

IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

P2D Biosciences

P2D, Inc. is a pharmaceutical company focused on developing new pharmaceuticals for brain disorders


Pradama, Inc. is a pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders. Pradama is developing compounds that target bone with the initial two products designed for osteoporosis treatment and an antineoplastic compound for the treatment of bone metastases.

Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

Neurelis Logo

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.